# Teen cannabis use linked to slower memory and thinking growth > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/teen-cannabis-use-linked-to-slower-memory-and-thinking-growth/ > **Published:** 2026-08-08T07:10:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:17:10-04:00 > **Clinical Summary:** Cannabis linked to slower adolescent memory and thinking growth. Key clinical implications for pediatric screening and family counseling. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchPediatricsNeurologyMental HealthSafetyTHCAnxiety Why This Matters Clinicians treating adolescents should screen for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) as regular consumption during critical developmental years may impair memory and cognitive processing speed, potentially affecting academic performance and long-term educational outcomes. This evidence helps inform counseling conversations with teens and parents about the specific neurodevelopmental risks of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during adolescence, when brain maturation is still occurring. Understanding these cognitive effects enables clinicians to better assess functional decline in young patients and advocate for early intervention or abstinence. Clinical Summary A longitudinal study of over 11,000 adolescents published in Neuropsychopharmacology found that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during the teenage years is associated with slower development of memory and cognitive processing speed compared to non-using peers. The research tracked participants’ neuropsychological performance over time, revealing that [adolescent cannabis exposure](https://cedclinic.com/cannabis-impairment-testing-arizona-marijuana-dui-laws/) appears to interfere with normal developmental trajectories of executive function and information processing rather than causing acute deficits. These findings are particularly significant given that the adolescent brain undergoes critical maturation of frontal and temporal regions through the mid-20s, a developmental window when cannabis exposure may have lasting neurodevelopmental consequences. For clinicians, this evidence supports counseling adolescent patients and their families about the cognitive risks of cannabis use during this vulnerable neurodevelopmental period, even for individuals without other risk factors. Clinicians should incorporate knowledge of these cognitive effects into risk-benefit discussions with adolescents and young adults considering or actively using cannabis, particularly those with academic or occupational demands requiring intact memory and processing speed. Dr. Caplan’s Take “This longitudinal data from over 11,000 adolescents adds meaningful evidence to what we’re seeing clinically regarding cannabis exposure during critical neurodevelopmental windows, though we should note that correlation doesn’t establish causation and we’d benefit from understanding which patterns of use carry the greatest risk. The takeaway for my practice is straightforward: adolescent brains are still actively wiring executive function and memory systems, so the precautionary principle suggests we counsel against use in this population until we have clearer safety data.” Clinical Perspective 🧠 [Adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) has been associated with slower cognitive development, particularly in memory and processing speed, according to longitudinal data from a large cohort study published in Neuropsychopharmacology. While this finding aligns with mechanistic understanding of [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) on the developing prefrontal cortex and hippocampus, clinicians should recognize that observational studies cannot definitively establish causation, and unmeasured confounders such as socioeconomic factors, concurrent [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/), mental health comorbidities, and genetic predisposition may partially explain the observed associations. The clinical relevance varies depending on frequency, timing, and duration of exposure, as occasional use may carry different risks than regular or heavy use during critical developmental windows. Given these limitations, the prudent clinical approach is to counsel adolescent patients and families about the potential cognitive risks of cannabis use while avoiding overstated claims, and to screen for cannabis use as 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Teen%20cannabis%20use%20linked%20to%20slower%20memory%20and%20thinking%20growth%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72886)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72886)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Teen%20cannabis%20use%20linked%20to%20slower%20memory%20and%20thinking%20growth%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D72886)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Natasha Wade, PhD, Highlights Slower Cognitive Growth After Teen Cannabis Use](https://cedclinic.com/slower-cognitive-growth-after-teen-cannabis-use/) - [Adolescent Cannabis Use Linked to Slower Cognitive Development – Technology Networks](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risks/) - [Major Study Links Teen Cannabis Use to Delayed Thinking and Memory Skills](https://cedclinic.com/teen-cannabis-delayed-memory-study/) 📰 Source: [https://www.sciencedaily.com/releases/2026/08/260806050726.htm](https://www.sciencedaily.com/releases/2026/08/260806050726.htm) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).